Clinical Trials Browser

Interventional × eliglustat × Gastrointestinal × Clear all

NCT06558773 2026-02-11

GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms